Robotic vs Thoracolaparoscopic Esophagectomy for Esophageal Cancer
JAMA Surgery · 01.11.2026 · 161 (11) · 1135
DOI: 10.1001/jamasurg.2026.4478 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA Surgery, erschienen am 01.11.2026. Verfasst von Felix Berlth und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral and Transplant Surgery, University Hospital Tuebingen, Germany. Hauptthemen laut MEDLINE: Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Laparoscopy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The optimal surgical approach for oncological thoracoabdominal esophagectomy for adenocarcinoma is unclear. Robot-assisted minimally invasive esophagectomy (RAMIE) may facilitate a more extensive lymphadenectomy compared with conventional minimally invasive esophagectomy (MIE), which is crucial to achieve a favorable oncological outcome.
Objective
To determine whether RAMIE results in a higher yield of resected lymph nodes compared with conventional MIE in patients undergoing surgery for esophageal or esophagogastric junction adenocarcinoma. Design, Setting, and Participants This was a phase 3 randomized clinical trial conducted between January 2021 and March 2025 at 4 high-volume tertiary referral centers in Mainz, Germany; Amsterdam, the Netherlands; Zurich, Switzerland; and Cologne, Germany. Patients with resectable adenocarcinoma of the esophagus or esophagogastric junction staged as cT1-4a, cN0-3, and cM0 were included. Both primary surgery and multimodal treatment settings were eligible. A total of 218 patients were initially randomized, 202 of whom completed the study and underwent transthoracic esophagectomy with follow-up up to 5 years.
Interventions
Participants were randomly assigned (1:1) to RAMIE or conventional MIE. Main Outcomes and Measures The primary end point was the number of resected lymph nodes, planned a priori and analyzed on a modified intention-to-treat basis. Secondary measures included luminal R0 resection rates, postoperative complication rates, 90-day mortality, and 1-year survival.
Results
Between 2021 and 2025, 218 patients were included in the study, 202 of whom (mean [SD] age, 64.8 [10.1] years; 181 [89.6%] male) underwent transthoracic esophagectomy (101 RAMIE and 101 MIE). The median number of resected lymph nodes was significantly higher in RAMIE compared to MIE (36 vs 32; P = .005). Luminal R0 resection was 99.0% with RAMIE and 97.0% with MIE. Rates of postoperative complications were similar between groups; 90-day mortality was 1.0% in the RAMIE group and 3.0% in the MIE group ( P = .62). There was no difference in survival after 1 year. Conclusions and Relevance In this study, robotic esophagectomy provided a more radical lymphadenectomy compared to conventional minimally invasive esophagectomy with equal results for surgical safety. These results support the use of robotic esophagectomy as a standard approach for adenocarcinoma of the esophagus or esophagogastric junction. Trial Registration ClinicalTrials.gov Identifier: NCT04306458
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of General, Visceral and Transplant Surgery, University Hospital Tuebingen, Germany.
- Department of Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.
- Cancer Center Amsterdam, Amsterdam, the Netherlands.
- University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
- Esophageal Cancer Center and Digestive Oncology Tumor Center, Hirslanden Medical Center, Zurich, Switzerland.
- Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital of Cologne, Germany.
Zitieren
APA
Berlth, F., Gisbertz, S. S., Tagkalos, E., Hadzijusufovic, E., Schneider, P. M., Fuchs, H., van Berge Henegouwen, M. I., Lozanovski, V. J., Ruurda, J. P., Goense, L., Schiesser, M., Bruns, C., Lang, H., van Hillegersberg, R., & Grimminger, P. P. (2026). Robotic vs Thoracolaparoscopic Esophagectomy for Esophageal Cancer. JAMA Surgery, 161(11), 1135. https://doi.org/10.1001/jamasurg.2026.4478
Vancouver
Berlth F, Gisbertz SS, Tagkalos E, Hadzijusufovic E, Schneider PM, Fuchs H, et al. Robotic vs Thoracolaparoscopic Esophagectomy for Esophageal Cancer. JAMA Surgery. 2026;161(11):1135. doi:10.1001/jamasurg.2026.4478
BibTeX
@article{Berlth2026,
author = {Berlth, Felix and Gisbertz, Suzanne S and Tagkalos, Evangelos and Hadzijusufovic, Edin and Schneider, Paul Magnus and Fuchs, Hans and van Berge Henegouwen, Mark I and Lozanovski, Vladimir J and Ruurda, Jelle P and Goense, Lucas and Schiesser, Marc and Bruns, Christiane and Lang, Hauke and van Hillegersberg, Richard and Grimminger, Peter P},
title = {Robotic vs Thoracolaparoscopic Esophagectomy for Esophageal Cancer},
journal = {JAMA Surgery},
year = {2026},
volume = {161},
number = {11},
pages = {1135},
doi = {10.1001/jamasurg.2026.4478}
}
EUVIMED